BPI-442096 / Betta Pharma - LARVOL DELTA

Xcovery SHP2 Inhibitor IND Approved by US FDA (Businesswire) - "Xcovery Holdings...announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational New Drug application (IND) of BPI-442096 , a small molecule Src homology region 2 domain-containing phosphatase 2 (SHP2) inhibitor, in solid tumors. Xcovery will initiate a phase I clinical trial in the United States to assess the tolerability, safety, and efficacy of BPI-442096."

IND • Oncology • Solid Tumor

Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients (clinicaltrials.gov) - P1 | N=230 | Not yet recruiting | Sponsor: Betta Pharmaceuticals Co., Ltd.

New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • BRAF • KRAS • NF1